News

Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

Scaling Heights to Cure Alzheimer’s

Mountaineer to Raise Awareness and Research Funding for Alzheimer’s by Climbing the Highest Summit on the World’s Seven Continents

 

Boston, Mass – Embarking on a year-long challenge that he hopes will end at the top of the Carstensz Pyramid, mountain climber and Alzheimer’s disease advocate Alan Arnette will take on the greater challenge of raising money for research and public awareness of Alzheimer’s disease, the nation’s sixth most deadly disease.

“The mental and physical demands of scaling seemingly insurmountable peaks are not unlike the everyday challenges faced by those living with Alzheimer’s disease and their caregivers,” said Arnette, who cared for his mother with Alzheimer’s until her death last year. “Both involve understanding personal limitations, reaching out for support and taking steps daily on a very long road.”

All of the money Arnette raises on his year-long campaign - The 7 Summits Climb for Alzheimer’s: Memories are Everything - will go to Cure Alzheimer’s Fund™, a non-profit organization dedicated to raising money for targeted research with the highest probability of slowing, stopping or reversing Alzheimer’s disease.

The Alzheimer’s Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc. is funding Arnette’s climbs. To support Arnette in raising funds for Cure Alzheimer’s Fund please visit http://curealz.org/donate/.

“Research is the key to solving the complexities of Alzheimer’s disease and Alan Arnette’s courageous fundraising efforts will help the Alzheimer’s community come one step closer to finding a cure,” said Tim Armour, President of the Cure Alzheimer’s Fund™.

“What are our life experiences and adventures about if not to create life-long memories that we can share and embellish, year after year, with friends and family? Memories are everything,” said Arnette, whose high-altitude climbs can be followed on Climb4AD.com and Facebook.com/Climb4AD.

An accomplished climber, Arnette retired from his job with a leading technology company to care for his mother, Ida, when she was diagnosed with Alzheimer’s. Since then, 54-year-old advocate has worked to raise money for this disease that has no known cure. With The 7 Summits Climb for Alzheimer’s, he hopes to raise awareness of the impact of the disease and is also striving to raise $1 million for research.

Arnette departs on the first of his seven climbs on November 24, 2010. The first peak is the 16,067-foot (4897 meter) Mt. Vinson Massif in Antarctica. By December 2011, he intends to reach the summits of:

  • Aconcagua, Argentina, South America – 22,841ft/6,926 m
  • Everest, Nepal, Asia – 29,035 ft/8,850 m
  • Denali, Alaska, North America – 20,320 ft/6,194 m
  • Elbrus, Russia, Europe – 18,481 ft/5,633 m
  • Kilimanjaro, Tanzania, Africa – 19,340 ft/ 5,896 m
  • Carstensz Pyramid, Indonesia, Oceania – 16,023 ft/4,884 m

Arnette is also taking on the extended challenge of climbing an eighth mountain, Mt. Kosciuszko in Australia, which is part of the Oceania continent.

Cure Alzheimer's Fund on WGBH's Greater Boston

Cure Alzheimer's Fund co-founer, Jeff Morby and Research Consortium Chairman, Rudy Tanzi were featured on the tv show Greater Boston, November 8th on WGBH channel 2 in Boston. Emily Rooney interviewed the two about the founding of Cure Alzheimer's Fund and success in the search for an Alzheimer's Cure.

Watch the Greater Boston show>

Mindy Todd also interviewed Rudy Tanzi and Jeff Morby on a live radio interview aired on NPR's The Point.

Listen to the The Point: Alzheimer's interview>

 

NPR Features Cure Alzheimer's Fund

Cure Alzheimer's Fund was featured this morning in a two-part segment on National Public Radio. The piece details the founding of Cure Alzheimer's Fund, our venture approach  and some of the science that is providing the way to a cure. WGBH in Boston introduced the piece:

For more than five million patients and their estimated ten million caregivers, Alzheimer's disease is a scourge, a memory-stealing, brain-clogging affliction that costs the United States more than $170 billion a year, though its true impact on the lives of American families is incalculable.

In the first installment of our 2-part series, "Venture Philanthropy: An Investor's Approach to Curing Alzheimer's," reporter Sean Corcoran introduces us to a small group of local business leaders who are using their proven investment techniques — and their personal fortunes — to assemble what they believe are the world's most promising researchers to slow, stop or reverse the disease.

Listen to Venture Philanthropy Part One: A Business Approach to Curing Alzheimer's Disease>

Listen to Venture Philanthropy Part Two: Wanted a Man on the Moon Project to Cure Alzheimer's Disease>

Read the WGBH article Mass. Venture Capitalists Invest in Alzheimer's Research>

Support The 7 Summits Climb for Alzheimer's

The 7 Summits Climb for Alzheimer's: Memories are Everything is a year-long challenge by mountain climber and Alzheimer's disease advocate Alan Arnette to scale the 7 Summits, the highest peaks on each continent. Alan climbs in memory of his mother, who passed away in 2009 from Alzheimer's disease. Alzheimer's disease is the 6th leading cause of death in the United States, with another person newly diagnosed every 70 seconds. It is estimated to affect more than 5 million people in the United States and more than 25 million people worldwide. That's why Alan chose to climb the 7 Summits to raise awareness of the impact of this debilitating disease and $1 million to advance Alzheimers research as it is his hope that scientists can find a way to slow or stop Alzheimer's disease.

Wall Street Journal highlights McCance at TEDMED

Katherine Hobson features Cure Alzheimer's co-founder, Henry McCance and his TEDMED talk in the Wall Street Journal HealthBlog. She writes:

Henry McCance, chairman emeritus of venture-capital firm Greylock Partners, says the conventional way of funding academic research is ineffective. And he’s got an alternative strategy, based on how things work in the VC world. . .

McCance said, for every dollar spent on Alzheimer’s research, another $400 is spent on caregiving to those who suffer from the disease.

Researchers spend up to 30% of their time filling out grant applications, he said. The entire system encourages incremental research on already-established theories that moves the ball forward, at most, only a yard or two. With the Cure Alzheimer’s Fund, where McCance is a founding board member, there’s a different approach. Namely:

  • Proactively identify world-class researchers and fund them.
  • Relieve them from bureaucracy.
  • Network researchers in a virtual organization and insist they share data and results promptly and collaboratively.
  • Challenge your researchers to dare to be great.

Read the full story>

 

Curing Alzheimer's by 2020-TEDMED and Sandra Day O'Connor

Ending the disease by 2020 is a hot topic. The ambitious goal was the focus of Henry McCance and Rudy Tanzi's TEDMED talk yesterday and was a key point in Sandra Day O'Connor's excellent op-ed in the New York Times from earlier in the week.

CNN.com featured a summary of the Tanzi/McCance TEDMED talk:

Dr. Rudolph Tanzi of the Cure Alzheimer's Fund laid out an ambitious goal of finding a cure for the illness by the year 2020. Tanzi and venture capitalist Henry McCance, who helped found the fund in 2004, described the partnership that led to the identification of new genes that seem to play a role in Alzheimer’s disease, genes that are potential targets for new drug therapies.

Read more about TEDMED>

We highly recommend reading The Age of Alzheimer's by Sandra Day O'Connor, Stanley Prusiner and Ken Dychtwald published on Oct. 27, 2010. Just to give you a glimpse of the important message, here's how the piece starts:

OUR government is ignoring what is likely to become the single greatest threat to the health of Americans: Alzheimer’s disease, an illness that is 100 percent incurable and 100 percent fatal. It attacks rich and poor, white-collar and blue, and women and men, without regard to party. A degenerative disease, it steadily robs its victims of memory, judgment and dignity, leaves them unable to care for themselves and destroys their brain and their identity — often depleting their caregivers and families both emotionally and financially.

Starting on Jan. 1, our 79-million-strong baby boom generation will be turning 65 at the rate of one every eight seconds. That means more than 10,000 people per day, or more than four million per year, for the next 19 years facing an increased risk of Alzheimer’s.

Read the NYT Op-ed>

Robert Malenka and Thomas Südhof join Research Consortium

Cure Alzheimer’s Fund is pleased to welcome two new members of the Research Consortium, Dr. Robert C. Malenka and Dr. Thomas C. Südhof. Researchers are invited to serve on the Research Consortium to guide Cure Alzheimer’s Fund-supported work and determine the “roadmap for research” for the most effective and efficient route to slowing, stopping and/or reversing Alzheimer’s disease.

Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, director of the Pritzker Laboratory, and co-director of the Stanford Institute for Neuro-Innovation and Translational Neurosciences at the Stanford University School of Medicine. He is a world leader in elucidating the molecular mechanisms by which neural circuits are reorganized by experience. His many contributions over the last 25 years have laid the groundwork for a much more sophisticated understanding of the mechanisms by which neurons communicate and the adaptations in synaptic communication which underlie all forms of normal and pathological behavior. He has been at the forefront of helping to apply the knowledge gained from basic neuroscience research to the treatment and prevention of major neuropsychiatric disorders.

Dr. Südhof is the Avram Goldstein Professor in the School of Medicine at Stanford University. He is also an investigator of the Howard Hughes Medical Institute, a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Südhof's research interests focus on the physiological and pathological mechanisms operating on the synapse, in particular on how synapses form, how they transmit signals and how they become abnormal during diseases such as Alzheimer’s disease and autism. His studies have identified key molecules in synapses, such as synaptotagmins, as the calcium sensors for neurotransmitter release, Munc18 as a major fusion protein at the synapse, and neurexins and neuroligins as central trans-synaptic cell adhesion molecules. One of the major current interests in his laboratory is to elucidate the relation of synaptic activity to synapse loss and neurodegeneration in Alzheimer’s disease.

 

Tanzi and Armour present at White House

The status of research in the United States to find a cure for Alzheimer’s disease was the focus of discussion at a White House-sponsored event on Sept. 21, World Alzheimer’s Day.

Cure Alzheimer’s Fund Research Consortium Chair Dr. Rudolph Tanzi and Tim Armour, president of Cure Alzheimer’s Fund, participated on a scientific panel at the White House event before a select audience of White House senior staff policymakers, leading scientists, advocates and others including Jeff Morby, chairman and co-founder of Cure Alzheimer’s Fund, and Melody Barnes, director of the White House Domestic Policy Council. The topics covered included the current status of biomarker identification for the disease, current thinking about prevention, the strength of the drug pipeline for Alzheimer’s and possible policy initiatives to accelerate progress toward a cure.

Panelists agreed more funding from both the public and private sectors needs to be invested in finding a cure and better treatments; and more aggressive efforts at creating public-private partnerships to provide focus for research efforts is crucial.

All agreed the nation cannot afford to wait, and the development of effective therapies to prevent or stop Alzheimer’s has to be a national priority, backed by a clear strategy and resources to implement it.

 

Scientific Advisory Board Member Given Lifetime Achievement Award

Marsel Mesulam was recognized for his extraordinary achievements in advancing Alzheimer’s research at the Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 in Honolulu. He is the recipient of the 2010 Bengt Winblad Lifetime Achievement Award. Dr. Mesulam’s research addresses the connectivity of the monkey brain, the organization of human cholinergic pathways, the representation of cognitive functions by large-scale neurocognitive networks and the neurobiology of dementias. Dr. Mesulam’s work on cholinergic pathways has been groundbreaking in understanding Alzheimer’s.

Dr. Mesulam was born in Istanbul in 1945. He received the degrees of bachelor of arts in 1968 and medical doctor in 1972, both from Harvard University. Dr. Mesulam was appointed professor of neurology at Harvard Medical School, where he founded and led the behavioral neurology unit of Boston’s Beth Israel Hospital. In 1994 he was appointed the Dunbar Professor of Neurology and Psychiatry and the director of the multidepartmental Cognitive Neurology and Alzheimer’s Disease Center at Northwestern University’s Feinberg School of Medicine in Chicago. He currently serves on the Cure Alzheimer’s Fund Scientific Advisory Board.

Exploring the Diabetes and Alzheimer’s Link

Researchers hypothesize part of the body’s natural defense against infection may underlie both diabetes and AD.

Cure Alzheimer’s researchers Dr. Rudy Tanzi, chairman of CAF’s Research Consortium and director of the Massachusetts General Genetics and Aging Research Unit, and Dr. Robert Moir from Massachusetts General Hospital were awarded funding from the Helmsley Trust through Cure Alzheimer’s Fund to explore the similarities between the protein amylin in diabetes and its analog in Alzheimer’s, both hallmarks of each disease’s pathology.

“We are deeply grateful for this generous gift from the Leona M. and Harry B. Helmsley Charitable Trust for a $600,000 grant to Cure Alzheimer’s Fund to be paid over two years,” said Tim Armour, president of Cure Alzheimer’s Fund. “This is an exceptional opportunity that is going to allow significant progress into better understanding the twin rising epidemics of diabetes and Alzheimer’s.”

Diabetes mellitus is estimated to affect some 23.6 million Americans today with incidence rates increasing every decade. People most at risk from type II (commonly called mature or late-onset) diabetes are in the same elderly population at risk of Alzheimer’s disease.

A pathological hallmark of both diabetes and Alzheimer’s is the deposition of insoluble proteinaceous deposits called amyloid. Diabetes and Alzheimer’s long have been known to share a broad array of clinical features and a large body of evidence suggests the pathologies of these two disorders are strongly linked. However, as yet no common molecular mechanism has been identified that can explain the long list of epidemiological commonalities between diabetes and Alzheimer’s.

The research, supported by the Helmsley Trust and Cure Alzheimer’s Fund, will focus on the toxic amyloid deposits thought to mediate cellular and tissue degeneration in patients with diabetes and patients with AD and, more specifically, will investigate the activities of the proteins that form diabetic and AD amyloids (for Alzheimer’s this is the Abeta peptide, and for diabetes it is a peptide called amylin).

Drs. Moir and Tanzi recently discovered that the Amyloid-beta protein, a key contributor and acknowledged by most researchers as the “key bad guy” in Alzheimer’s pathology, may have an unsuspected side. The prevailing theory was that Abeta has no function other than as a waste product created by the brain. But research published in the March issue of the journal PLoS One, by Drs. Moir and Tanzi show the protein may be part of the body’s natural defense against infection. This research suggests that Abeta has a very positive function—the peptide may be a natural antibiotic protecting the brain from invading microbes and defending against parasites.

“These data change the way we look at Abeta,” says Dr. Tanzi. “For years, we thought that Abeta was just metabolic garbage produced as a byproduct of other processes within the brain, but new data suggest it is a normal component of the brain’s innate immune system.” Rob Moir adds “Our laboratory has recently shown that Abeta is, in fact, a potent naturally occurring antibiotic. In preliminary experiments we have shown that amylin also appears to be a potent natural antibiotic.”

It appears both proteins may be members of an ancient family of biomolecules called antimicrobial peptides (AMPs) that are the first line of defense against invading organisms. AMPs are the foot soldiers of our innate immune system- an older defense system separate from the antibodies and cells of adaptive immunity.

Notably, while AMPs are critically important for killing invading pathogens, many can also cause collateral damage to host tissue. Aggregation is a key mechanism for the function of AMPs and at least five cause amyloid pathologies. Moir and Tanzi’s findings link, for the first time, the pathologies of diabetes and AD at the molecular level by identifying a common and totally unanticipated antimicrobial function for amylin and Abeta.

These findings suggest that the same or similar site-specific overactive innate immune response to a perceived infection (real or incorrectly identified) may underlie both diabetes and AD. In the brain this response causes Alzheimer’s, when it occurs in the pancreas the result is diabetes.

Confirmation of this hypothesis would prompt a major re-think of the origins of these diseases. In addition, it would identify the pathways of innate immunity as new drug targets for treating, and possibly even preventing diabetes and AD.